462-463 / 1676
Indication protocol
Head and neck cancer
Endpoint
OARs
∆NTCP
Level of
evidence after
external
validation
Moderate-to severe
xerostomia (patient-rated
EORTC QLQ-HN35)
• Parotid gland
contralateral
≥ 10% Level 3 → 2a
Dysphagia grade ≥ II
(CTCAE)
• Superior PCM
• Oral cavity
≥ 10% Level 3 → 2a
Tube feeding
dependence
• Superior PCM
• Inferior PCM
• Parotid gland
contralateral
• Esophageal inlet
muscle
≥ 5% Level 3 → 2a